HC Wainwright Rates Traws Pharma (TRAW) hold, $1 Price Target

HC Wainwright has revised its outlook on Traws Pharma, lowering the rating to hold, a 17.10% upside from the current price.

By EarningsIQ Research Desk · Published Jun 19, 2026, 3:03 AM EDT · Updated Jun 24, 2026, 10:03 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated Traws Pharma, Inc. ($TRAW) "hold" with a $1 price target on June 18, 2026.

Since the rating, $TRAW is down 2.4% after 1 week, down 28.2% after 1 month and down 56.5% to date (from the $0.85 close on Jun 18, 2026).

TRAW Traws Pharma, Inc.

$0.37 -72.18% year to date

Daily close · Oct 16, 2026

Key Points

HC Wainwright downgraded Traws Pharma to a hold rating with a new price target of $1.0 on June 18, 2026.
HC Wainwright's $1 price target implies 17.10% upside from Traws Pharma, Inc.'s ($TRAW) current $0.85 share price.
Shares of NasdaqCM:TRAW are trading around $0.80, with a market cap of approximately $12.9 million.
Peer funds like Dauntless Investment Group added 416,998 shares, while Squadron Capital reduced their holdings by 201,826 shares.

Get $TRAW trade alerts by text

We text you when insiders, Congress or big funds trade $TRAW. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Traws Pharma, Inc. alert may contain errors. Disclosures

HC Wainwright has adjusted its stance on Traws Pharma, Inc. (NasdaqCM: TRAW) by downgrading the stock to a hold rating and setting a price target of $1.0. This change was announced on June 18, 2026, amid a backdrop of fluctuating share prices and market conditions.

Analyst rating track record

HC Wainwright & Co. vs. the S&P 500

YTD return +49% hypothetical

All-time return +148.06% S&P 500 +29.05%

vs. S&P 500 +119.01% ahead of the index

Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in Traws Pharma

Several institutional investors have been active in Traws Pharma. Dauntless Investment Group added 416,998 shares, bringing its total to 416,998 shares valued at approximately $763,106. Meanwhile, Squadron Capital Management trimmed its holdings by 201,826 shares, leaving it with 511,714 shares worth about $936,437. Other investors, such as Adage Capital Partners and Ikarian Capital, maintained their positions without any changes.

Traws Pharma, Inc. Stock Up 74.3%

Shares of NasdaqCM:TRAW are currently trading near $0.80. Traws Pharma has a market capitalization of about $12.9 million. The stock's 52-week range has seen a low of $0.64 and a high of $3.27. The company has a 50-day moving average of $1.43 and a 200-day moving average of $1.87. With a current ratio of 0.429 and a quick ratio of 0.365, the company faces liquidity challenges.

12-month forecast

$TRAW price target

Traws Pharma, Inc. daily closes and this analyst's $1 target. Not advice.

Insider Buying and Selling at Traws Pharma, Inc.

Insiders at Traws Pharma have been active as well. On April 16, 2026, OrbiMed Advisors LLC made multiple purchases, including one of 597,729 shares at an average price of $1.67. Earlier in the year, on March 8, 2026, Chief Financial Officer Parker Charles Nolan acquired 104,544 shares.

Analysts Set New Price Targets

On June 18, 2026, HC Wainwright & Co. downgraded Traws Pharma to a hold rating with a $1.0 price target. Previously, on May 20, 2026, the firm reiterated a buy rating with a much higher target of $8.0. As of now, the consensus recommendation is a buy, with a mean target price of $8.0 based on one analyst opinion.

About Traws Pharma

Traws Pharma, Inc., based in Newtown, Pennsylvania, is a clinical-stage biopharmaceutical company specializing in small synthetic molecules for respiratory viral diseases and cancer. The company is developing treatments for conditions like COVID-19 and influenza, including TRX01 and Tivoxavir marboxil. Traws Pharma also focuses on cancer therapies such as narazaciclib and rigosertib. Led by CEO Dr. Iain D. Dukes, the company employs four people.

Bottom Line

The downgrade by HC Wainwright reflects a more cautious outlook on Traws Pharma, which faces ongoing challenges in a competitive biotech sector. Investors keep a close watch on analyst ratings and institutional activity to gauge market sentiment. It's important to remember that these ratings are based on past performance and market conditions.